Target Gene Table
VIS IDVirusEnsembl IDGene TypeTarget GeneOncogeneTumor Suppressor GeneNCBI IDUniprot ID
TVIS30052257HIVENSG00000118260.15protein_codingCREB1YesNo1385P16220
Q53X93
Q5U0J5
TVIS20032878HPVENSG00000118260.15protein_codingCREB1YesNo1385P16220
Q53X93
Q5U0J5
TVIS20039382HPVENSG00000118260.15protein_codingCREB1YesNo1385P16220
Q53X93
Q5U0J5
TVIS20046358HPVENSG00000118260.15protein_codingCREB1YesNo1385P16220
Q53X93
Q5U0J5
TVIS20055557HPVENSG00000118260.15protein_codingCREB1YesNo1385P16220
Q53X93
Q5U0J5
TVIS20014243HPVENSG00000118260.15protein_codingCREB1YesNo1385P16220
Q53X93
Q5U0J5
TVIS50000018MLVENSG00000118260.15protein_codingCREB1YesNo1385P16220
Q53X93
Q5U0J5
TCGA Plot Options
Drug Information
GeneCREB1
DrugBank IDDB00131
Drug NameAdenosine phosphate
Target IDBE0000958
UniProt IDP16220
Regulation Typeactivator
PubMed IDs16879221; 17083486; 17122581; 17300755; 17324065
CitationsUlfhammer E, Larsson P, Karlsson L, Hrafnkelsdottir T, Bokarewa M, Tarkowski A, Jern S: TNF-alpha mediated suppression of tissue type plasminogen activator expression in vascular endothelial cells is NF-kappaB- and p38 MAPK-dependent. J Thromb Haemost. 2006 Aug;4(8):1781-9.@@Saha B, Singh SK, Sarkar C, Bera R, Ratha J, Tobin DJ, Bhadra R: Activation of the Mitf promoter by lipid-stimulated activation of p38-stress signalling to CREB. Pigment Cell Res. 2006 Dec;19(6):595-605.@@Kozinn J, Mao L, Arora A, Yang L, Fibuch EE, Wang JQ: Inhibition of glutamatergic activation of extracellular signal-regulated protein kinases in hippocampal neurons by the intravenous anesthetic propofol. Anesthesiology. 2006 Dec;105(6):1182-91.@@Perlis RH, Purcell S, Fagerness J, Cusin C, Yamaki L, Fava M, Smoller JW: Clinical and genetic dissection of anger expression and CREB1 polymorphisms in major depressive disorder. Biol Psychiatry. 2007 Sep 1;62(5):536-40. Epub 2007 Feb 14.@@Brenhouse HC, Howe ML, Stellar JR: Differential activation of cAMP response element binding protein in discrete nucleus accumbens subregions during early and late cocaine sensitization. Behav Neurosci. 2007 Feb;121(1):212-7.
GroupsApproved; Investigational; Nutraceutical; Withdrawn
Direct ClassificationPurine ribonucleoside monophosphates
SMILESNC1=C2N=CN([C@@H]3O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]3O)C2=NC=N1
PathwaysLeigh Syndrome; Histidinemia; Guanidinoacetate Methyltransferase Deficiency (GAMT Deficiency); Fatty Acid Metabolism; Gentamicin Action Pathway; Pyruvate Dehydrogenase Complex Deficiency; Purine Nucleoside Phosphorylase Deficiency; Hyperprolinemia Type II; Glutamate Metabolism; Clarithromycin Action Pathway; Argininosuccinic Aciduria; Pyruvate Decarboxylase E1 Component Deficiency (PDHE1 Deficiency); Hyperinsulinism-Hyperammonemia Syndrome; Butyrate Metabolism; Pyruvate Metabolism; Pentose Phosphate Pathway; Propanoate Metabolism; Glycine and Serine Metabolism; Selenoamino Acid Metabolism; Thiamine Metabolism; Oxytetracycline Action Pathway; Tetracycline Action Pathway; Carbamoyl Phosphate Synthetase Deficiency; Hyperprolinemia Type I; Histidine Metabolism; Cystathionine beta-Synthase Deficiency; Arginine and Proline Metabolism; Roxithromycin Action Pathway; Purine Metabolism; Ammonia Recycling
PharmGKBPA164744376
ChEMBLCHEMBL752